JNCE - ジョンス・セラピュ―ティクス （Jounce Therapeutics Inc.） ジョンス・セラピュ―ティクスJNCEのチャート
JNCEの企業情報
| symbol | JNCE |
|---|---|
| 会社名 | Jounce Therapeutics Inc （ジョンス・セラピュ―ティクス） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Biotechnology: Biological Products (No Diagnostic Substances) |
| 業種 | バイオテクノロジ―_メディカルリサ―チ 医療関連（Health Care） |
| 概要 | 事業概要 ジャウンス・セラピューティックス(Jounce Therapeutics Inc.)は臨床段階の免疫療法会社である。同社は免疫システムが腫瘍を攻撃し、患者に長続きする利益を提供する治療法を開発することにより、癌の治療法を変革することに従事する。同社は、翻訳科学プラットフォームを使用して、最初に腫瘍内の特定の細胞型に焦点を当てて標的の優先順位を付け、適切な治療法に合致するように設計された関連バイオマーカーを特定する。主要製品候補であるJTX-2011は、誘導性T細胞CO刺激薬（ICOS）に結合して活性化するモノクローナル抗体であり、第II相試験中である。 ジョンス・セラピュ―ティクスは米国のバイオ医薬品企業。臨床段階で、がん免疫療法の開発に従事する。免疫療法によりがん細胞を攻撃し、患者に長期にわたり効果が出る治療法を開発する。同社プラットフォ―ムによりがん細胞をタ―ゲットにし、バイオマ―カ―を特定し適切な治療を行うことを目標とする。本社所在地はマサチュ―セッツ州ケンブリッジ。 Jounce Therapeutics, Inc. is a clinical-stage immunotherapy company dedicated to transforming the treatment of cancer by developing therapies that enable the immune system to attack tumors and provide long-lasting benefits to patients through a biomarker-driven approach. Jounce currently has multiple development stage programs ongoing while simultaneously advancing additional early-stage assets from its robust discovery engine based on its Translational Science Platform. Jounce's highest priority program, JTX-8064, is a LILRB2 (ILT4) receptor antagonist shown to reprogram immune-suppressive tumor associated macrophages to an anti-tumor state in preclinical studies. A Phase 1 clinical trial, named INNATE, for JTX-8064 as a monotherapy and in combination with JTX-4014, Jounce's internal PD-1 inhibitor, or pembrolizumab is currently enrolling patients with advanced solid tumors. Jounce's most advanced product candidate, vopratelimab, is a monoclonal antibody that binds to and activates ICOS, and is currently being studied in the SELECT Phase 2 trial. JTX-4014 is a PD-1 inhibitor intended for combination use in the INNATE and SELECT trials and with Jounce's broader pipeline. Additionally, Jounce exclusively licensed worldwide rights to JTX-1811, a monoclonal antibody targeting CCR8 and designed to selectively deplete T regulatory cells in the tumor microenvironment, to Gilead Sciences, Inc. |
| 本社所在地 | 780 Memorial Drive Cambridge MA 02139 USA |
| 代表者氏名 | Richard Murray リチャード・マレー |
| 代表者役職名 | President Chief Executive Officer Director 社長兼最高経営責任者（CEO） |
| 電話番号 | +1 857-259-3840 |
| 設立年月日 | 40969 |
| 市場名 | NASDAQ National Market System |
| ipoyear | 2017年 |
| 従業員数 | 112人 |
| url | www.jouncetx.com |
| nasdaq_url | https://www.nasdaq.com/symbol/jnce |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -31.61000 |
| 終値（lastsale） | 6.415 |
| 時価総額（marketcap） | 209306233.62 |
| 時価総額 | 時価総額（百万ドル） 182.06220 |
| 売上高 | 売上高（百万ドル） 61.63900 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） -50.64880 |
| 当期純利益 | 当期純利益（百万ドル） -31.15000 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Jounce Therapeutics Inc revenues decreased 25% to $30.6M. Net loss applicable to common stockholders increased from $3.8M to $17.7M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Higher net loss reflects Employee compensation R&D increase of 27% to $11.5M (expense) Stock-based Compensation in SGA increase from $839K to $2.3M (expense). |
JNCEのテクニカル分析
JNCEのニュース
Board Member at Jounce Therapeutics Exercises Options Worth $236K 2023/05/04 15:03:55 Benzinga
Gayle Barbara Duncan , Board Member at Jounce Therapeutics (NASDAQ: JNCE ), reported a large exercise of company stock options on May 4, according to a new SEC filing. What Happened: A Form 4 filing from the U.S. Securities and Exchange Commission on Thursday showed that Duncan, Board Member at Jounce Therapeutics, a company in the Health Care sector, just exercised stock options worth 125,761 shares of JNCE stock with an exercise price of $5.68. Jounce Therapeutics shares are trading down 0.0% at $1.88 at the time of this writing on Thursday morning. Since the current price is $1.88, this makes Duncan''s 125,761 shares worth $236,430. Now trade stocks online … Full story available on Benzinga.com
Jounce Therapeutics Board Member Acquires 104,363 Shares After Exercising Company Stock Options 2023/05/04 15:03:48 Benzinga
Luis Diaz , Board Member at Jounce Therapeutics (NASDAQ: JNCE ), reported a large exercise of company stock options on May 4, according to a new SEC filing. What Happened: A Form 4 filing from the U.S. Securities and Exchange Commission on Thursday showed that Diaz, Board Member at Jounce Therapeutics, a company in the Health Care sector, just exercised stock options worth 104,363 shares of JNCE stock with an exercise price of $8.05. Jounce Therapeutics shares are trading down 0.0% at $1.88 at the time of this writing on Thursday morning. Since the current price is $1.88, this makes Diaz''s 104,363 shares worth $196,202. Now trade stocks online … Full story available on Benzinga.com
Director at Jounce Therapeutics Exercises Options Worth $111K 2023/05/04 15:03:40 Benzinga
Luisa SalterCid , Director at Jounce Therapeutics (NASDAQ: JNCE ), reported a large exercise of company stock options on May 4, according to a new SEC filing. What Happened: A Form 4 filing from the U.S. Securities and Exchange Commission on Thursday showed that SalterCid, Director at Jounce Therapeutics, a company in the Health Care sector, just exercised stock options worth 59,250 shares of JNCE stock with an exercise price of $8.46. Jounce Therapeutics shares are trading down 0.0% at $1.88 at the time of this writing on Thursday morning. Since the current price is $1.88, this makes SalterCid''s 59,250 shares worth $111,390. Now trade stocks online commission free … Full story available on Benzinga.com
Jounce Therapeutics Director Acquires 51,400 Shares After Exercising Company Stock Options 2023/05/04 15:03:33 Benzinga
Jigar Raythatha , Director at Jounce Therapeutics (NASDAQ: JNCE ), reported a large exercise of company stock options on May 4, according to a new SEC filing. What Happened: A Form 4 filing from the U.S. Securities and Exchange Commission on Thursday showed that Raythatha, Director at Jounce Therapeutics, a company in the Health Care sector, just exercised stock options worth 51,400 shares of JNCE stock with an exercise price of $5.04. Jounce Therapeutics shares are trading down 0.0% at $1.88 at the time of this writing on Thursday morning. Since the current price is $1.88, this makes Raythatha''s 51,400 shares worth $96,632. Now trade stocks online commission … Full story available on Benzinga.com
Jounce Therapeutics Board Member Acquires 1,883,269 Shares After Exercising Company Stock Options 2023/05/04 15:03:23 Benzinga
CA RICHARD MURRAY , Board Member at Jounce Therapeutics (NASDAQ: JNCE ), reported a large exercise of company stock options on May 4, according to a new SEC filing. What Happened: A Form 4 filing from the U.S. Securities and Exchange Commission on Thursday showed that MURRAY, Board Member at Jounce Therapeutics, a company in the Health Care sector, just exercised stock options worth 1,883,269 shares of JNCE stock with an exercise price of $6.53. Jounce Therapeutics shares are trading down 0.0% at $1.88 at the time of this writing on Thursday morning. Since the current price is $1.88, this makes MURRAY''s 1,883,269 shares worth $3,540,545. Now trade stocks online … Full story available on Benzinga.com
Powerful stocks to Increase Your Investments: Meta Materials Inc. (NASDAQ:MMAT), Jounce Therapeutics, Inc. (NASDAQ:JNCE) 2023/04/11 04:53:52 Stock Equity
MMAT has seen its SMA50 which is now -35.66%. In looking the SMA 200 we see that the stock has seen a -57.60%. JNCE has seen its SMA50 which is … The post Powerful stocks to Increase Your Investments: Meta Materials Inc. (NASDAQ:MMAT), Jounce Therapeutics, Inc. (NASDAQ:JNCE) appeared first on Stocks Equity .
Jounce Therapeutics and Redx Pharma Terminate Proposed Merger 2023/04/03 09:19:02 Investing.com
https://www.investing.com/news/pro/jounce-therapeutics-and-redx-pharma-terminate-proposed-merger-432SI-3047391
Termination of Proposed Business Combination of Jounce Therapeutics, Inc. and Redx Pharma plc 2023/04/03 06:00:00 GlobeNewswire
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION.
Baird maintains Jounce Therapeutics at Neutral 2023/03/28 11:52:36 Investing.com
https://www.investing.com/news/pro/jounce-therapeutics-inc-receives-investment-bank-analyst-rating-update-3042293
Jounce Therapeutics PT Lowered to $2 at Baird 2023/03/28 10:45:04 Investing.com
https://www.investing.com/news/pro/jounce-therapeutics-pt-lowered-to-2-at-baird-432SI-3042156
Jounce Therapeutics PT Lowered to $16 at Raymond James 2022/08/30 18:01:02 Investing.com
https://www.investing.com/news/pro/jounce-therapeutics-pt-lowered-to-16-at-raymond-james-432SI-2882806
JNCE stock drops as lung cancer therapy fails in mid-stage trial (NASDAQ:JNCE) 2022/08/30 12:39:41 Seeking Alpha
Cambridge, Massachusetts-based Jounce Therapeutics, Inc
Boom Or Bust: What Are Jounce Therapeutics Inc.’s (NASDAQ:JNCE) Future Prospects? 2022/08/20 18:00:00 Marketing Sentinel
Jounce Therapeutics Inc. (NASDAQ:JNCE)’s traded shares stood at 0.66 million during the last session, with the company’s beta value hitting 1.22. At the close of trading, the stock’s price was $4.65, to imply a decrease of 0.00% or $0.0 in intraday trading. The JNCE share’s 52-week high remains $9.81, putting it -110.97% down since that … Boom Or Bust: What Are Jounce Therapeutics Inc.’s (NASDAQ:JNCE) Future Prospects? Read More »
Jounce Therapeutics, Inc. (JNCE) CEO Richard Murray on Q2 2022 Results - Earnings Call Transcript 2022/08/05 21:51:02 Seeking Alpha
Jounce Therapeutics, Inc. (NASDAQ:NASDAQ:JNCE) Q2 2022 Earnings Conference Call August 04, 2022 08:00 AM ET Company Participants Eric Laub - Vice President-Investor Relations Richard Murray…